Linnaeus Therapeutics is a development stage biotech company engaged in the identification and development of small molecule agents for the treatment of cancer. They are a Penn Center for Innovation UPstart company
Linnaeus Therapeutics is focused on the development and commercialization of novel, small molecule oncology therapeutics that target a novel G protein-coupled receptor, known as GPER, or GPR30.
Linnaeus Therapeutics was founded in 2016 by Todd Ridky & Christopher Natale and is based in Haddonfield, New Jersey. The company was formed and launched in partnership with the UPstart incubator at the University of Pennsylvania's Penn Center for Innovation (PCI).
Linnaeus Therapeutics' lead molecule, LNS8801, is in the final stages of preclinical development. The company expects to begin its phase 1 clinical program in the near-term. In addition to developing GPER agonists, Linnaeus is also currently focusing on developing small molecules that activate other G protein-coupled receptors to engage tumor-suppressive cellular signaling pathways.
Linnaeus Therapeutics is backed by Kairos Ventures & Penn Medicine Co-Investment Fund at the University of Pennsylvania. The company raised $12M from a latest "Series B" financing on Sep 17, 2019. Bringng Linnaeus' total funding to $16.4M to-date.